Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 11/20 | 0.47 |
| ▸ | CA2 | P00918 | 11/20 | 0.47 |
| ▸ | CA12 | O43570 | 10/20 | 0.47 |
| ▸ | CA9 | Q16790 | 10/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3157516 | 0.87 | CYP2D6 (0.69) | CYP2D6CYP3A4CA1CA2CA12 | |
| SCHEMBL2563975 | 0.74 | CYP3A4 (0.70) | CYP2D6CYP3A4CA1CA2CA12 | |
| SCHEMBL13989375 | 0.73 | CA2 (0.49) | CYP2D6CYP3A4CA1CA2CA12 | |
| SCHEMBL3204797 | 0.73 | CA2 (0.49) | CYP2D6CYP3A4CA1CA2CA12 | |
| SCHEMBL30380602 | 0.73 | CYP2D6 (0.68) | CYP2D6CYP3A4CA1CA2CA12 | |
| SCHEMBL30380384 | 0.72 | CYP2D6 (0.66) | CYP2D6CYP3A4CA1CA2CA12 | |
| SCHEMBL11516144 | 0.71 | CYP2D6 (1.00) | CYP2D6CYP3A4CA1CA2CA12 | |
| SCHEMBL28079518 | 0.71 | CYP3A4 (0.66) | CYP2D6CYP3A4CA1CA2CA12 | |
| SCHEMBL10790350 | 0.70 | ALDH1A1 (0.62) | CA1CA2CA12CA9MMP1 | |
| SCHEMBL11520559 | 0.69 | CYP2D6 (0.81) | CYP2D6CYP3A4CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449247-B2 | Compositions and methods for enhancing immune response | AVIVAGEN INC. (CA) | 2019-10-22 | — | — | US | claimed |
| EP-2273989-A1 | COMBINATION THERAPY FOR THE TREATMENT OF BACTERIAL INFECTIONS | Interface Biologics Inc. (CA) | 2011-01-19 | — | — | EP | claimed |
| US-20100062974-A1 | COMBINATION THERAPY FOR THE TREATMENT OF BACTERIAL INFECTIONS | INTERFACE BIOLOGICS, INC. (CA) | 2010-03-11 | — | — | US | claimed |
| WO-2009124386-A1 | COMBINATION THERAPY FOR THE TREATMENT OF BACTERIAL INFECTIONS | INTERFACE BIOLOGICS INC. (CA) | 2009-10-15 | — | — | WO | claimed |
| EP-0741570-B1 | PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO ANTIINFECTIVE MEDICATIONS | SEARLE & CO (US) | 2003-05-07 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| US-6172069-B1 | CONTROLLING TIME OF ADMINISTERING | G. D. SEARLE & COMPANY | 2001-01-09 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0786999-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1999-01-20 | — | — | EP | claimed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| US-20200197310-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-4665100-A | REDUCTION OF CARRYOVER TO SUBSEQUENT LOTS | ELI LILLY AND COMPANY (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0060680-A1 | Process for formulating a medicated animal feed premix | ELI LILLY AND COMPANY (US) | 1982-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062974-A1 | COMBINATION THERAPY FOR THE TREATMENT OF BACTERIAL INFECTIONS | ELANE, TLR5, SERPINB1 | CYP2D6 1330/4885CYP3A4 1852/4885CA1 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.